Infectious diseases Archives - Page 8 of 33

Clinical Articles

The WHO has declared Eris a ‘variant of interest’. How is it different from other Omicron variants?

The World Health Organization (WHO) classified it as a “variant under monitoring” on July 19 after a surge in COVID

Clinical Articles

Long COVID: brain function still affected for some up to two years after infection – new research

Difficulties with cognitive functions or skills, such as the ability to recall memories, concentrate on tasks, or find the right words in conversation, are commonly reported following a COVID infection.

Videos

New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Podcasts

COVID-19 – The latest information

Molnupiravir is still effective and protecting your most vulnerable patients

Clinical Articles

Common diabetes drug metformin could protect against long COVID

here are no drugs to treat long COVID – a condition that affects around 2 million people in the UK alone

Videos

Protein based COVID-19 vaccine

In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains the recombinant protein nanoparticle COVID-19 vaccine with a proprietary adjuvant, including the mechanism of action, efficacy, and tolerability; and provides an update on boosters, indications, and access (8 mins).

Podcasts

COVID update – Boosters, side effects, new waves

Vaccine-related injury, long COVID, more on boosters.

Videos

Influenza vaccines for older adults in the 2023 influenza season

In this Product Explainer, Public Health Physician A/Prof John Litt AM explains the currently funded adjuvanted quadrivalent influenza vaccine for people 65 years and over and how it fits in the 2023 influenza season (6 mins).This product explainer is supported by Seqirus

Podcasts

COVID Update – It’s not over yet

The current COVID situation- protect your vulnerable patients.

Clinical Articles

When it comes to vaccinations – don’t forget the old

Don’t forget routine immunisations and use any patient contact as an opportunity for vaccination—says Professor Nick Wood of the National Centre for Immunisation Research & Surveillance at the University of Sydney.

Clinical Articles

Cytomegalovirus lies dormant in most US adults and is the leading infectious cause of birth defects, but few have heard of it

“Why didn’t anyone tell me about this virus?” is a frequent response I hear from parents upon learning their newborn is infected with cytomegalovirus, or CMV. Although more than half of the U.S. population will be infected with CMV by the age of 40 and the disease is common worldwide, few people have ever heard of it.

Expert/s: Healthed

Podcasts

COVID update – The 5th wave

WHO vs ATAGI booster advice, which do we use? Antivirals - positive evidence for Molnupiravir emerges.

Infectious diseases

The WHO has declared Eris a ‘variant of interest’. How is it different from other Omicron variants?

The World Health Organization (WHO) classified it as a “variant under monitoring” on July 19 after a surge in COVID

Long COVID: brain function still affected for some up to two years after infection – new research

Difficulties with cognitive functions or skills, such as the ability to recall memories, concentrate on tasks, or find the right words in conversation, are commonly reported following a COVID infection.

New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

COVID-19 – The latest information

Molnupiravir is still effective and protecting your most vulnerable patients

Common diabetes drug metformin could protect against long COVID

here are no drugs to treat long COVID – a condition that affects around 2 million people in the UK alone

Protein based COVID-19 vaccine

COVID update – Boosters, side effects, new waves

Vaccine-related injury, long COVID, more on boosters.

Influenza vaccines for older adults in the 2023 influenza season

In this Product Explainer, Public Health Physician A/Prof John Litt AM explains the currently funded adjuvanted quadrivalent influenza vaccine for people 65 years and over and how it fits in the 2023 influenza season (6 mins).This product explainer is supported by Seqirus

COVID Update – It’s not over yet

The current COVID situation- protect your vulnerable patients.

When it comes to vaccinations – don’t forget the old

Don’t forget routine immunisations and use any patient contact as an opportunity for vaccination—says Professor Nick Wood of the National Centre for Immunisation Research & Surveillance at the University of Sydney.

Cytomegalovirus lies dormant in most US adults and is the leading infectious cause of birth defects, but few have heard of it

COVID update – The 5th wave

WHO vs ATAGI booster advice, which do we use? Antivirals - positive evidence for Molnupiravir emerges.

Get the app

Site

Company

Connect

Legal

Healthed

Upcoming Healthed Webcast

Tune in for "Facial rashes case studies - Practical guide to assessment and management" lecture

Tuesday 9th June, 7pm - 9pm AEST

Speaker

Dr Philip Tong

Consultant Dermatologist; Founder, DermScreen, Dermatology Junction; Visiting Medical Officer, St Vincent’s Hospital Sydney

What does it mean when a facial red rash does not respond to topical steroids and gets worse with the treatment? Dermatologist Dr Philip Tong presents a series of cases with this scenario.

Infectious diseases

The World Health Organization (WHO) classified it as a “variant under monitoring” on July 19 after a surge in COVID

Difficulties with cognitive functions or skills, such as the ability to recall memories, concentrate on tasks, or find the right words in conversation, are commonly reported following a COVID infection.

Molnupiravir is still effective and protecting your most vulnerable patients

here are no drugs to treat long COVID – a condition that affects around 2 million people in the UK alone

Vaccine-related injury, long COVID, more on boosters.

In this Product Explainer, Public Health Physician A/Prof John Litt AM explains the currently funded adjuvanted quadrivalent influenza vaccine for people 65 years and over and how it fits in the 2023 influenza season (6 mins).This product explainer is supported by Seqirus

The current COVID situation- protect your vulnerable patients.

Don’t forget routine immunisations and use any patient contact as an opportunity for vaccination—says Professor Nick Wood of the National Centre for Immunisation Research & Surveillance at the University of Sydney.

WHO vs ATAGI booster advice, which do we use? Antivirals - positive evidence for Molnupiravir emerges.

Save time on registrations, track CPD, listen to full podcasts... sign in to your Healthed account now

Don't have an existing account? Sign up today

Extra Details

Healthed

Upcoming Healthed Webcast

Tune in for "Facial rashes case studies - Practical guide to assessment and management" lecture

Tuesday 9th June, 7pm - 9pm AEST

Speaker

Dr Philip Tong

Consultant Dermatologist; Founder, DermScreen, Dermatology Junction; Visiting Medical Officer, St Vincent’s Hospital Sydney

What does it mean when a facial red rash does not respond to topical steroids and gets worse with the treatment? Dermatologist Dr Philip Tong presents a series of cases with this scenario.